Digoxin: Difference between revisions

Revision as of 19:34, 27 February 2014

Digoxin
DIGOXIN injection^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DIGOXIN tablet^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

For patient information, click here.

Digoxin INN is a purified cardiac glycoside similar to Digitoxin extracted from the foxglove plant, Digitalis lanata,^[1] which was discovered by William Withering. Its corresponding aglycone is digoxigenin, and its acetyl derivative is acetyldigoxin. Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication.

LANOXIN^®, DIGOXIN^®, DIGOX^®.

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Digoxin}}
-{{CMG}}; {{AE}} {{AZ}}
+{{CMG}}; {{AE}} {{AK}}
 '''''For patient information, click <u>[[Digoxin (patient information)|here]]'''''</u>.